-
Dr. Hongfei Zhang’s Team: Latest Stage Data Revealed for China’s “Sprout” Project, Aiding Clinical Cure for Children with Chronic Hepatitis B
Chronic hepatitis B is the leading cause of liver disease in Chinese children, posing a serious threat to their health. The “Sprout” project is China’s first large-scale real-world study focusing on antiviral treatment for chronic hepatitis B in children. Led by Dr. Hongfei Zhang’s team, with Shenzhen Third People’s Hospital as the main center, the…
-
AASLD 2023: 17 Must-See Studies
From November 10th to 14th, the annualHepatology Digest conference, the American Association for the Study of Liver Diseases (AASLD) 2023 held in Boston, USA. This event gathers the latest academic developments, clinical research findings, and major academic presentations in the field of liver disease. The following is a summary of 17 highly anticipated studies scheduled…
-
Headline: AASLD Hot Updates on MASLD from the 2023 Annual Meeting
On November 7, 2023, at 12:30 PM local time in Boston, the American Association for the Study of Liver Diseases (AASLD) held its sole pre-conference press briefing on Metabolic Associated Fatty Liver Disease (MASLD). Chaired by conference president Professor Norah Terrault, the event featured presentations by Professor Phuc Le of the Cleveland Clinic Lerner College…
-
AASLD Voice of China丨Dr. Fengmin Lu: A1762T/G1764A Mutation Promotes HBV Replication, HNF1α Holds Promise as a Novel Therapeutic Target
From November 10th to 14th, the annual highlight of hepatology, the American Association for the Study of Liver Diseases (AASLD) 2023, was grandly held in Boston, USA. With over 200 abstracts from Chinese experts and scholars selected for oral presentations or poster sessions, the achievements were commendable. Congratulations to all! Dr. Fengmin Lu’s team from…
-
AASLD Voice of China | Peking University Hepatology Institute Shines with 10 Achievements at AASLD 2023
From November 10th to 14th, the annual international event in hepatology—the American Association for the Study of Liver Diseases (AASLD) 2023—was grandly held in Boston, USA. According to incomplete statistics, more than 200 abstracts from Chinese experts and scholars were selected for oral presentations or poster exchanges at this conference, achieving fruitful results. Congratulations are…
-
AASLD Review | New Therapies for Hepatitis B: Vebicorvir, Selgantolimod, Bepirovirsen, Therapeutic Vaccines, and More
Currently, some patients with chronic hepatitis B (CHB) can achieve clinical cure through interferon-based antiviral treatment. To pursue clinical cure for a larger population, there is a flurry of activity in the development of new drugs. Six studies on new therapies for hepatitis B were selected for presentation at the 2023 American Association for the…
-
🔬 Deciphering the Future of RCC Treatment: Prof. Manuela Schmidinger on LITESPARK Studies and HIF-2α Inhibitors
At the recent European Society for Medical Oncology (ESMO) conference, a critical spotlight was on the groundbreaking results of the LITESPARK-003 and LITESPARK-005 studies. Understanding the implications of these studies…
-
🔬 Highlighting TAR-200: Prof. Andrea Necchi’s Perspective on Cancer Treatment Advances
Oncology Frontier brings you an insightful overview of the TAR-200 delivery system, a promising development in cancer therapy, through the lens of Professor Andrea Necchi’s expertise. As a distinguished figure…
Connecting Medical Expertise through Media